Magnetic Resonance Spectroscopy in the Psychosis Risk Syndrome

描述（由申请人提供）：近几十年来，精神病的概念发生了变化，国际上针对识别和治疗精神病高风险青年的密集努力以及新出现的亚临床精神病症状在普通人群中出现的数据证明了这一点。患有“轻度精神病综合征”（APS）的个体除了言语/行为紊乱、主观痛苦和临床求助外，还表现出低水平的现实扭曲（不寻常的思想内容、知觉失常、多疑/偏执）。该综合征在表型上与精神分裂症持续存在，是研究APS和精神分裂症可能共同存在的病理生理机制的关键机会。一个重要的潜在机制可能在抑制性gaba能和兴奋性谷氨酸能系统中发现。磁共振波谱（MRS）已经实现了GABA和谷氨酸/谷氨酰胺浓度的区域测量，允许这些神经递质的体内测定。未服药的精神分裂症患者显示内侧前额叶皮质（mPFC）中Glx（谷氨酸/谷氨酰胺浓度）和GABA水平升高，这是大脑的一个区域，与精神分裂症和APS的功能和结构成像研究有关。我们发现慢性精神病患者的mPFC对苯二氮卓类药物表现出更大的敏感性，这表明gaba能异常。一个关键的问题是这些异常是否可以在APS状态下检测到，这个探索性的R21提案将通过测量年轻APS患者的皮质GABA和Glx来解决这个问题，并将其与匹配的健康对照者和首发精神病（FEP）患者进行比较。在Aim 1中，我们将检查APS个体在mPFC和枕皮质的GABA和Glx水平，测试相对于健康对照和服用FEP的患者，APS受试者在mPFC的GABA和Glx水平将升高的预测。相比之下，预测APS和FEP受试者枕叶皮层的GABA和Glx减少。在目标2中，我们将评估APS个体的mPFC功能，并测试来自同一区域的GABAergic和Glx信号的相关性。我们预测，在APS患者中，GABAergic和Glx信号将与mPFC BOLD信号呈负相关（而非药物FEP患者）。该R21的预期影响有三个方面：1)在r01水平的提案可以检查基线GABA和Glx作为结果（转化为精神病以及临床改善）的预测因子之前，这是必不可少的第一步；2)纵向研究的必不可少的第一步，将检查GABA和Glu的变化及其与结果的关联；3)设计针对APS中GABA/Glx系统的治疗干预的机制原理。

DESCRIPTION (provided by applicant): The concept of psychosis has shifted in recent decades, as evidenced by an intensive international effort aimed at identifying and treating youth at high risk of psychosis and emerging data that subclinical psychotic symptoms appear in the general population. Individuals with an 'attenuated psychosis syndrome' (APS) present with low levels of reality distortion (unusual thought content, perceptual aberrations, suspiciousness/paranoia), in addition to disorganized speech/behavior, subjective distress and clinical help- seeking. The syndrome is phenotypically continuous with schizophrenia and a critical opportunity in which to study pathophysiological mechanisms that may be common to both APS and schizophrenia. One important potential mechanism may be found in inhibitory GABAergic and excitatory glutamatergic systems. Magnetic resonance spectroscopy (MRS) has enabled the regional measurement of GABA and glutamate/glutamine concentrations, permitting the in vivo assay of these neurotransmitters. Unmedicated patients with schizophrenia have shown elevations of Glx (glutamate/glutamine concentration) and GABA levels in the medial prefrontal cortex (mPFC), a region of the brain implicated in functional and structural imaging studies in schizophrenia and APS. We found the mPFC to exhibit greater sensitivity to benzodiazepine challenge in chronic psychotic patients, suggesting that GABAergic abnormalities. A critical question is whether these abnormalities may be detected in the APS state, which this exploratory R21 proposal will address by measuring cortical GABA and Glx in young persons with APS, compared to matched healthy control subjects and first episode psychosis (FEP) patients. In Aim 1, we will examine GABA and Glx levels in APS individuals in the mPFC and occipital cortex, testing the prediction that GABA and Glx levels will be elevated in APS subjects in the mPFC, relative to healthy controls and medicated FEP patients. In contrast, GABA and Glx are predicted to be reduced in the occipital cortex of both APS and FEP subjects. In Aim 2, we will assess mPFC function in APS individuals and test correlations with GABAergic and Glx signal from this same region. We predict that GABAergic and Glx signals will be inversely correlated with mPFC BOLD signal in the APS patients (but not medicated FEP patients). The anticipated impact of this R21 is three-fold: 1) An essential first step required before an R01-level proposal can examine baseline GABA and Glx as predictors of outcome (conversion to psychosis as well as clinical improvement), 2) An essential first step for a longitudinal study that will examine change in GABA and Glu and associations with outcome; and 3) A mechanistic rationale for designing therapeutic interventions that target GABA/Glx systems in APS.